期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HPV16E7抗原的HLA-A2限制性细胞毒性T淋巴细胞表位的筛选与鉴定 被引量：6

Screening and Identification of Predicted Epitopes of HLA-A2-restricted Cytotoxic T Lymphocytes Derived from the HPV16 E7 Antigen
原文传递
导出
摘要 目的筛选和鉴定人工合成的人乳头瘤病毒16型E7抗原人白细胞抗原A2分子限制性细胞毒性T细胞预测表位。方法对预测的E7抗原人白细胞抗原A2分子限制性细胞毒性T细胞(CTL)表位运用标准Fmoc方案进行合成与纯化,采用标准51Cr释放试验检测特异性CTL诱导活性。结果筛选并鉴定出E711-19(YMLDLQPET)和E749-57(RAHYNIVTF)2条人乳头瘤病毒16型E7抗原人白细胞抗原A2分子限制性CTL表位。结论E711-19(YMLDLQPET)和E749-57(RAHYNIVTF)抗原性较强,有可能作为HPV感染治疗用肽疫苗的候选表位。 Objective To screen and identify the predicted epitopes of synthesized predicted HLA-A2-restricted cytotoxic T lymphocytes (CTLs) derived from HPV16 E7 antigen. Methods The predicted epitopes of HLA-A2-restricted CTLs derived from HPV16 E7 antigen were synthesized and purified with Standard Fmoc assays, and the standard 51Cr release assay was used to determine their activities to induce specific CTL. Results Two epitopes of HLA-A2-restricted CTLs, namely E711-19 (YMLDLQPET) and E749-57 (RAHYNIVTF) derived from HPV16 E7 antigen were identified. Conclusion E711-19 (YMLDLQPET) and E749-57 (RAHYNIVTF) have antigenicity, and may be the candidates for development of peptide vaccine in the treatment of HPV infections.
作者 徐云升 郝飞 宋志强 钟白玉 郝进 叶庆佾
机构地区 第三军医大学西南医院皮肤科
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2004年第5期283-284,共2页 Chinese Journal of Dermatology
基金 国家自然科学基金(30070698)
关键词 HPV16 E7抗原 HLA-A2 限制性细胞毒性 T淋巴细胞表位 筛选 鉴定 检测 人乳头瘤病毒16型 Papillomavirus, human Epitopes, T-lymphocyte E7 antigen
分类号 R392 [医药卫生—免疫学]
  • 相关文献

参考文献7

  • 1徐云升,郝飞,钟白玉,郝进,叶庆佾,4郑江.人乳头瘤病毒16 E7抗原细胞毒性T细胞预测表位合成肽的纯化与鉴定[J].中华皮肤科杂志,2003,36(5):284-284. 被引量：3
  • 2Fujie T, Tahara K, Tanaka F, et al. A MAGE-1-encoded HLAA24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int J Cancer, 1999, 80:169-172.
  • 3de Jong A, O'Neill T, Khan AY, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine, 2002, 20:3456-3464.
  • 4Oiso M, Eura M, Katsura F, et al. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Int J Cancer, 1999, 81:387-394.
  • 5徐云升,郝飞.HPV16型E7抗原表位的研究进展[J].中华皮肤科杂志,2003,36(5):300-302. 被引量：2
  • 6Yewdell JW,Hill AB.Viral interference with antigen presentation.Nat Immunol,2002,3:1019-1025.
  • 7唐旭,赵玉铭,董小平,何春涤,王雅坤,陈洪铎.尖锐湿疣患者外周血中HPVDNA的检测[J].中华皮肤科杂志,2003,36(5):258-260. 被引量：13

二级参考文献30

  • 1Castellanos MR, Hayes RL, Maiman MA.Synthetic peptides induce a cytotoxic response against human papillomavirus type18. Gynecol Oncol, 2001, 82:77-83.
  • 2Rudolf MP, Man S, Melief C J, et al. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res, 2001, 7(3 Suppl):788s-795s.
  • 3Ruesch MN, Stubenrauch F, Laimins LA.Activation of papillomavirus late gene transcription and genome amplification upon differentiation in semisolid medium is coincident with expression of involucrin and transglutaminase but not keratin-10. J Virol, 1998, 72:5016-5024.
  • 4Frazer IH, Thomas R, Zhou J, et al. Potential strategies utilised by papillomavirus to evade host immunity. Immunol Rev, 1999,168:131-142.
  • 5Xu L, Sanchez A, Yang Z, et al. Immunization for Ebola vires infection. Nat Med,1998, 4:37-42.
  • 6Ronco LV, Karpova AY, Vidal M, et al.Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev, 1998, 12:2061-2072.
  • 7Doan T, Chambers M, Street M, et al.Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. Virology, 1998, 244:352-364.
  • 8Pumpens P, Razanskas R, Pushko P, et al.Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes.Intervirology, 2002, 45:24-32.
  • 9Sidney J, Grey HM, Kubo RT, et al. Practical, biochemical and evolutionary implications of the discovery of ttLA class I supermotifs. Immunol Today, 1996, 17:261-266.
  • 10Gulukota K, Sidney J', Sette A, et al. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol, 1997, 267:1258-1267.

共引文献14

同被引文献55

  • 1王临虹,邱琇,郑睿敏,狄江丽.我国宫颈癌流行病学状况及防治策略的回顾与展望[J].中国妇幼卫生杂志,2010,1(3):146-149. 被引量：76
  • 2张晓姝,万敏,张培因,王华,王燕媚,王丽颖,于永利.宫颈癌CTL表位疫苗TATHPV蛋白的构建与表达[J].中国生物制品学杂志,2005,18(2):93-96. 被引量：1
  • 3李艳佳,齐凤英,左连富,郭建文,张俊峰,宣晓梅,陈兴宽.人乳头瘤病毒16型E7基因修饰小鼠骨髓树突状细胞诱导的细胞免疫应答[J].中华微生物学和免疫学杂志,2005,25(2):136-136. 被引量：2
  • 4蒋明军,王书崎,龚向东,余艳华,陈强,高省,尹跃平,韩国柱,孙建方.尖锐湿疣皮损中人乳头瘤病毒基因分型研究[J].中华皮肤科杂志,2005,38(5):262-264. 被引量：39
  • 5Cassetti MC, McElhiney SP, Shahabi V, et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine, 2004, 22: 520-527.
  • 6Angeline M, Merle E, Moroianu J. The E7 oncoprotein of high-risk human papillomavirus type 16 enters the nucleus via a nonclassical Ran-dependent pathway. Virology, 2003, 317: 13-23.
  • 7Schaeffer A J, Nguyen M, Liem A, et al. E6 and E7 oncoproteins induce distinct patterns of chromosomal aneuploidy in skin tumors from transgenic mice. Cancer Res, 2004, 64: 538-546.
  • 8Walboomers JM,Jacobs MV,Manos MM,et al.Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.J Pathol,1999,189:12-19.
  • 9Nilges K,Hohn H,Pilch H,et al.Human papillomavirus type 16 E7 peptide-directed CD8^+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.J Virol,2003,77:5464-5474.
  • 10Scholten KB,Schreurs MW,Ruizendaal J J,et al.Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.Clin Immunol,2005,114:119-129.

引证文献6

二级引证文献14

中华皮肤科杂志
2004年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部